ストックスクリーナーアプリを入手
6.67
5.39%
-0.38
アフターアワーズ：
6.50
-0.17
-2.55%
Regenxbio Inc (RGNX) 最新ニュース
When (RGNX) Moves Investors should Listen - news.stocktradersdaily.com
Clear Street sets Regenxbio stock Buy rating, $50 target - Investing.com India
Clear Street sets Regenxbio stock Buy rating, $50 target By Investing.com - Investing.com UK
5 Reasons To Buy Regenxbio Right Now (NASDAQ:RGNX) - Seeking Alpha
REGENXBIO partners with Nippon Shinyaku for MPS therapies - MSN
Regenxbio’s Triple Threat: Partnered Programs, DMD Progress And In-House Manufacturing - insights.citeline.com
RegenXBio Positioned Favorably Amid Competitor Safety Concerns, Justifying Buy Rating - TipRanks
REGENXBIO’s DMD Gene Therapy RGX-202 Generates Microdystrophin Expression in Additional Patients Treated in Phase 1/2 Trial - CGTLive™
Regenxbio Rises After Duchenne Update And Sarepta Safety Scare - insights.citeline.com
Sarepta safety update on Elevidys boosts Regenxbio, hurts Solid Bio - MSN
Regenxbio’s RGX-202 continues to show promise in DMD - The Pharma Letter
Regenxbio’s DMD gene therapy drives 122.3% biomarker uptick in three-year-old - Clinical Trials Arena
Regenxbio stock target raised to $29 at Raymond James By Investing.com - Investing.com Canada
REGENXBIO reports promising gene therapy trial results By Investing.com - Investing.com South Africa
Baird maintains Regenxbio stock outperform rating, $39 target By Investing.com - Investing.com South Africa
Baird maintains Regenxbio stock outperform rating, $39 target - Investing.com
Regenxbio stock target raised to $29 at Raymond James - Investing.com India
Regenxbio up 4% following additional data on Duchenne gene therapy asset - MSN
Regenxbio Touts Positive Biomarker Data From Duchenne Muscular Dystrophy Gene Therapy Trial - Benzinga
Regenxbio Says New Data Support Potential Gene Therapy for Duchenne Muscular Dystrophy - MarketScreener
REGENXBIO reports promising gene therapy trial results - Investing.com India
REGENXBIO: New Interim Data Reinforces Potential Of RGX-202Quick Facts - Nasdaq
Breakthrough: REGENXBIO DMD Gene Therapy Achieves Unprecedented 122% Protein Expression - StockTitan
Regenxbio stock up, Solid Bio down post Sarepta update (RGNX) - Seeking Alpha
Regenxbio at UBS Virtual CNS Day: Gene Therapy Advancements - Investing.com
Regenxbio at UBS Virtual CNS Day: Gene Therapy Advancements By Investing.com - Investing.com Canada
H.C. Wainwright cuts Regenxbio stock target to $34, maintains buy By Investing.com - Investing.com Philippines
REGENXBIO Inc. (NASDAQ:RGNX) Is About To Turn The Corner - Yahoo Finance
H.C. Wainwright cuts Regenxbio stock target to $34, maintains buy - Investing.com India
Regenxbio completes its BLA filing for first potential gene therapy for MPS II - The Pharma Letter
REGENXBIO Earnings Call Highlights Strategic Progress - TipRanks
Earnings call transcript: Regenxbio Q4 2024 beats EPS forecast, stock surges - Investing.com Australia
Stifel maintains Buy on Regenxbio stock, $40 target By Investing.com - Investing.com South Africa
Stifel maintains Buy on Regenxbio stock, $40 target - Investing.com India
A Glimpse Into The Expert Outlook On Regenxbio Through 5 Analysts - Benzinga
Regenxbio Inc earnings beat by $0.12, revenue fell short of estimates - Investing.com Australia
Regenxbio Inc (RGNX) Q4 2024 Earnings Call Highlights: Strategic Advances and Financial Resilience - Yahoo Canada Finance
REGENXBIO Reports Progress in Gene Therapy Pipeline - TipRanks
Regenxbio Q4 License & Royalty Revenue USD 21.214 Million -March 13, 2025 at 05:37 pm EDT - Marketscreener.com
Regenxbio Inc (RGNX) Q4 2024 Earnings: EPS Beats Estimates at -$1.01, Revenue Misses at $21.2 Million - GuruFocus.com
Regenxbio (RGNX) Reports Q4 Loss, Lags Revenue Estimates - Yahoo Finance
Regenxbio: Q4 Earnings Snapshot - San Antonio Express-News
1.23%
1.63%
大文字化:
|
ボリューム (24 時間):